Clinical trialNo phase (not a drug trial)Completed
A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia
- Outcome
- Results posted; single-arm, no comparison
- Phase
- No phase (not a drug trial)
- Status
- Completed
- Study type
- Interventional
- Start
- July 2007
- Ended
- August 2010
- Enrollment
- 36 participants
- Sites
- 2
- Primary outcomes
- Change in Serum Albumin
- Sponsor type
- Academic / other
- Results posted
- 8 September 2011
- Last update
- 23 March 2017
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 23 March 2017
- Primary outcome
- Change in Serum AlbuminEicosapentaenoic Acid (Lovaza): 4.0 (3.10 to 4.70), n = 14Values: median g/dL, Full RangeTime frame: 6 weeks per patientNo analysis posted for this outcome (outcome 1)
- Participants
- Eicosapentaenoic Acid (Lovaza): 36 started, 14 completed
- Serious adverse events
- Eicosapentaenoic Acid (Lovaza): 4 of 36Participants with at least one serious adverse event, of those at risk, as posted
1 secondary outcome
- Number of Participants With Proteasome Activity That Was Inhibited in the Range of 6%-29%.
- Eicosapentaenoic Acid (Lovaza) 9, n=14 [Participants]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The data collected through this pilot study will allow us to increase our understanding of cancer cachexia and the effect of Eicosapentaenoic Acid (EPA) on cancer cachexia. Our long-term goal is to improve nutritional treatment and reduce illness in the cancer patient population.
Detailed description public domain (ClinicalTrials.gov)
People who have cancer can get what is called cancer cachexia (CC). The symptoms of CC include getting full quickly when eating (early satiety), loss of appetite, weakness resulting in weight loss and loss of lean body mass. Even a weight loss of 5% in cancer patients reflects poor health, hospitalization, and a higher rate of illness. Research shows that the elderly are at higher risk for deficiency of vitamins and trace minerals. Other pre-existing chronic diseases and drug therapies in this population may increase the needs of certain nutrients. Recent studies have also shown that advanced malnutrition is much more difficult to treat in the elderly than in younger adults, and the consequences of failure to treat it delays recovery and can decrease function and quality of life. At this time, the ways to treat CC include giving medications to increase appetite and giving nutritional supplements that are high in calories and protein. Recent studies have shown that certain types of fats that are present in fish, walnuts and other foods that we eat called Eicosapentaenoic acid (EPA) may help with weight gain, especially gain in muscle and improve quality of life in patients with pancreatic cancer. However, EPA has never been studied in prevention of cancer cachexia in cancer patients showing early signs of weight loss. Based on these early, small studies, it is clear that we need to study if and how EPA can prevent loss of muscle and weight in cancer patients and prevent this from becoming worse.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Change in Serum Albumin [6 weeks per patient]. Median, g/dL (Full Range). Eicosapentaenoic Acid (Lovaza) (n=14): 4.0 (3.10 to 4.70).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants With Proteasome Activity That Was Inhibited in the Range of 6%-29%. [6 weeks per patient]. Number, Participants. Eicosapentaenoic Acid (Lovaza) (n=14): 9.